Akero Therapeutics reports a 39% improvement in cirrhosis patients using EFX. See why AKRO stock is soaring with the ...

Wall Street expects a year-over-year increase in earnings on higher revenues when Equifax (EFX) reports results for the quarter ended December 2024. While this widely-known consensus outlook is ...

Citi analysts boosted their price target on Akero Therapeutics (NASDAQ:AKRO) shares to $80 from the previous $65, while ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

Akero's SYMMETRY Phase 2b study showed 50mg EFX achieved 24% cirrhosis reversal in MASH patients, with improvements in liver ...

Akero Therapeutics announced statistically significant results from a Phase 2b trial of efruxifermin this week, a fibroblast ...

Akero Therapeutics has revealed preliminary outcomes from its Phase IIb study of EFX in individuals with compensated ...

Akero Therapeutics has hit a home run, reporting statistically significant results in two key 96-week metabolic ...

Akero Therapeutics, Inc., a biotechnology company focusing on metabolic dysregulation diseases, provided updates regarding ...

Akero Therapeutics (AKRO) stock soared 115% after the company reported positive long-term results from a Phase 2b study of ...

On Monday, at 10:23 a.m. GMT-5, Akero Therapeutics ( AKRO, Financials) saw its stock soar by 106.63%, closing at $54.10, ...

Morgan Stanley lowered the firm’s price target on Equifax (EFX) to $316 from $320 and keeps an Overweight rating on the shares. While the firm ...